Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.76 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27822584 | 0.98 | MAOB (0.73) | MAOBADORA2BPTGS2ALOX15NPC1 | |
| Hydrochloric Acid SCHEMBL87683 | 0.98 | MAOB (0.73) | MAOBADORA2BPTGS2ALOX15NPC1 | |
| SCHEMBL1253672 | 0.86 | MAOB (1.00) | MAOBADORA2BPTGS2MAOA | |
| SCHEMBL30059662 | 0.86 | MAOB (1.00) | MAOBADORA2BPTGS2MAOA | |
| SCHEMBL13655497 | 0.86 | MAOB (0.62) | MAOBADORA2BALOX15NPC1MAPT | |
| SCHEMBL8761733 | 0.85 | MAOB (0.61) | MAOBADORA2BALOX15NPC1MAPT | |
| SCHEMBL11253210 | 0.85 | MAOB (0.67) | MAOBADORA2BPTGS2ALOX15NPC1 | |
| SCHEMBL6345667 | 0.82 | KMT2A (0.61) | MAOBADORA2BNPC1MAPTRAB9A | |
| SCHEMBL28793372 | 0.82 | MAOB (0.54) | MAOBADORA2BPTGS2NPC1MAPT | |
| SCHEMBL1299217 | 0.82 | MAOB (0.58) | MAOBADORA2BNPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051949-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-02-15 | — | — | US | claimed |
| CN-108239054-B | Preparation method of benzofuran-3-carboxylic acid | 上海奥博生物医药股份有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-108239054-A | A kind of preparation method of benzofuran -3- carboxylic acids | 上海奥博生物医药技术有限公司 | 2018-07-03 | — | — | CN | claimed |
| WO-2013033520-A1 | A METHOD FOR REGULATING SKIN PIGMENTATION | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-07 | — | — | WO | claimed |
| EP-1877365-B1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2010-11-10 | — | — | EP | claimed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | claimed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | claimed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | claimed |
| EP-1425286-A1 | SUBSTITUTED 7-AZA[2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2004-06-09 | — | — | EP | claimed |
| WO-2003022856-A1 | SUBSTITUTED 7-AZA[2.2.1] BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-20 | — | — | WO | claimed |
| JP-57031616-A | — | — | None | — | — | JP | disclosed |
| US-20260130917-A1 | ANTIVIRAL COMPOSITION FOR CORONAVIRUS OR INFLUENZA VIRUS, USING NATURAL PRODUCTS, AND USE THEREOF | KOREA ADVANCED INST OF SCIENCE AND TECHNOLOGY (KR) | 2026-05-14 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| EP-0485962-A2 | New tricyclic compounds | SYNTEX (U.S.A.) INC. (US) | 1992-05-20 | — | — | EP | disclosed |
| EP-0045473-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING A BENZOFURAN-CARBOXAMIDE DERIVATIVE AS THE ACTIVE INGREDIENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-05-02 | — | — | EP | disclosed |
| US-4353923-A | MUSCLE RELAXANTS, ANTIINFLAMMATORY, ANALGESIC | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1982-10-12 | — | — | US | disclosed |
| JP-S5731616-A | RELAXING AGENT FOR MUSCLE COMPRISING BENZOFURANCARBOXYLIC ACID AMIDE | KYOWA HAKKO KOGYO CO LTD | 1982-02-20 | — | — | JP | disclosed |
| EP-0045473-A1 | A pharmaceutical composition containing a benzofuran-carboxamide derivative as the active ingredient | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1982-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051949-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM6, TRPM2 | MAOB 1881/4885ADORA2B 885/4885PTGS2 283/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MAOB 165/4885ADORA2B 1561/4885PTGS2 1406/4885 |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | MAOB 251/4885ADORA2B 192/4885PTGS2 2817/4885 |
| US-20260130917-A1 | ANTIVIRAL COMPOSITION FOR CORONAVIRUS OR INFLUENZA VIRUS, USING NATURAL PRODUCTS, AND USE THEREOF | ACE2, ACE, OAT | MAOB 203/4885ADORA2B 2855/4885PTGS2 2260/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | MAOB 1863/4885ADORA2B 461/4885PTGS2 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.